Ensheng Medical Completes Nearly CNY 100 Million Series A Financing to Lead Comprehensive Solutions for Venous Diseases

VCBeat has learned that Shanghai Ensheng Medical Technology Co., Ltd. (“Ensheng Medical”) recently announced the completion of its Series A financing round, raising nearly RMB 100 million. The round was led by Med-Fine Capital, with participation from Zeyue Capital and Laishi Capital. Existing investors, Furong Capital and Jiuzhi Xinfei Capital, continued to increase their stakes. Ruiling Capital served as the exclusive financial advisor for this financing round. The funds will be primarily used to accelerate the research and development of venous intervention products, advance clinical trials, and strengthen the R&D team.

Ensheng Medical, established in November 2018, is a high-tech enterprise dedicated to the research and development of comprehensive solutions for peripheral venous diseases. It possesses internationally leading innovative technologies with independent intellectual property rights. Its product portfolio includes venous stent systems, rapid closure systems for varicose vein treatment, and venous thrombus removal systems.

Since its inception, Ensheng Medical has focused on the field of peripheral venous intervention. With strong independent R&D capabilities, the company has developed several innovative projects targeting venous disease indications such as iliac vein compression syndrome (IVCS), varicose veins, deep vein thrombosis (DVT), and pulmonary embolism (PE). Adhering to the mission of “Benefiting the Public, Earning Trust through Excellence,” Ensheng Medical is committed to becoming a leader in interventional treatment for peripheral venous diseases, creating “new domestic” interventional medical products, and providing patients with high-quality, high-performance peripheral venous medical solutions.